CLOSTRIDIUM DIFFICILE - COLITIS ASOCIADA A ANTIBIOTICOTERAPIA

Vínculos.

- Bauer MP, Kuijper EJ. Potential sources of Clostridium difficile in human infection. Infect Dis Clin North Am. 2015 Mar;29(1):29-35. doi: 10.1016/j.idc.2014.11.010.
- Han S, Shannahan S, Pellish R. Fecal Microbiota Transplant: Treatment Options for Clostridium difficile Infection in the Intensive Care Unit. J Intensive Care Med. 2015 Jul 3. pii: 0885066615594344.
- García-García-de-Paredes A, Rodríguez-de-Santiago E, Aguilera-Castro L, Ferre-Aracil C, López-Sanromán A. Trasplante de microbiota fecal. Gastroenterologia y Hepatologia. March 1, 2015:38(3): 123-134.
- Rodríguez-Pardo D, Mirelis B, Navarro F. Infecciones producidas por Clostridium difficile. Enferm Infecc Microbiol Clin. 2013; 31:254-63. doi: 10.1016/j.eimc.2012.12.010
- 131-147 Collini PJ, Bauer M, Kuijper E, Dockrell DH. Clostridium difficile infection in HIV-seropositive individuals and transplant recipients. Review. J Infection, Feb 2012;64(2):131-147.
- Germansky KA, Kelly CP. Clostridium difficile Infection. Review. Hospital Medicine Clinics, January 2012;1(1):e69–e86.
- Pant C, Sferra TJ, Deshpande A, Minocha A. Clinical approach to severe Clostridium difficile infection: Update for the hospital practitioner. Eur J Intern Med, Dec 2011. 22(6):561-568.
- Cheng AC, Ferguson JK, Richards MJ, Robson JM, Gilbert GL, McGregor A, et al. Australasian Society for Infectious Diseases guidelines for the diagnosis and treatment of Clostridium difficile infection. MJA 2011; 194 (7): 353-358
- Karas JA, Enoch DA, Aliyu SH. A review of mortality due to Clostridium difficile infection. Review. J Infection, July 2010;61(1):1-8
- Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol, Jul 2009;7:526-536. doi:10.1038/nrmicro2164
- Ciarán P. Kelly, MD (Discussant). A 76-year-old man with recurrent Clostridium difficile-associated diarrhea: review of C. difficile infection. JAMA. Mar 4 2009;301(9):954-62. Breve revisión, caso clínico.

CLOSTRIDIUM PERFRINGENS - ENTERITIS

- Caro Gómez N, Galán Sánchez F, Guerrero Lozano I, Cornejo Saucedo MA. Infecciones por gérmenes anaerobios. Tétanos y botulismo. Medicine, 2014; 11( 55):3259-3268. Integración. En Clinical Key.
- Guerra Alves G, Machado de Ávila RA, Chávez-Olórtegui CD, Faria Lobato FC. Clostridium perfringens epsilon toxin: The third most potent bacterial toxin known. Review. Anaerobe, December 2014;30: 102-107.
- G. Allaart JG, Van Asten AJAM, Gröne A. Predisposing factors and prevention of Clostridium perfringens-associated enteritis. Review. Comparative Immunology, Microbiology and Infectious Diseases, September 2013;36(5):449-464.
- Hernández-Rocha C, Naour S, Álvarez-Lobos M, Paredes-Sabja D. Infecciones causadas por Clostridium difficile: una visión actualizada. Revista chilena de infectología, 2012;29(4), 434-445.
- Lindström M, Heikinheimo A, Lahti P, Korkeala H. Novel insights into the epidemiology of Clostridium perfringens type A food poisoning. Food Microbiology, April 2011;28(2):192-198.
- Rodriguez-Palacios A, Reid-Smith RJ, Staempfli HR, Weese JS. Clostridium difficile survives minimal temperature recommended for cooking ground meats. Anaerobe, Oct 2010;16(5):540–542 http://dx.doi.org/10.1016/j.anaerobe.2010.05.004
- Van Asten AJAM, Nikolaou GN, Gröne A. The occurrence of cpb2-toxigenic Clostridium perfringens and the possible role of the β2-toxin in enteric disease of domestic animals, wild animals and humans. Review Article. Vet J, Feb 2010;183(2):135-140

CLOSTRIDIUM TETANI y CLOSTRIDIUM BOTULINUM

Última revisión 6 agosto 2015

Hecho en México, Universidad Nacional Autónoma de México (UNAM), todos los derechos reservados 2011. Esta página puede ser reproducida con fines no lucrativos, siempre y cuando no se mutile, se cite la fuente completa y su dirección electrónica. De otra forma requiere permiso previo por escrito de la institución. Créditos

Sitio web administrado por: Dra. Teresa Uribarren Berrueta. Contacto